Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II MT-4561 dose-escalation in advanced solid tumors
jRCT2031250227Phase 2Recruiting
- Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of MT-4561 in head and neck squamous cell carcinoma (HNSCC), non-small cell lung cancer (NSCLC), esophageal cancer and 13 more, sponsored by Mitsubishi Tanabe Pharma Corporation. Primary endpoints: Incidence of adverse events and dose-limiting toxicities (DLTs) - Part 1 and Number of patients with adverse events (AEs) - Part 1. Started Sep 2025; status: recruiting.
02
Drugs
MT-4561
03
Conditions
head and neck squamous cell carcinoma (HNSCC)non-small cell lung cancer (NSCLC)esophageal cancergastric cancer (GC)biliary cancer
Beyond the preview
Go deeper on jRCT2031250227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250227.